Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size, Share, Analysis, Growth: By Treatment Method: Surgery, Chemotherapy, Radiation, Targeted Immunotherapy; By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical, Others; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Outlook

The Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment market is expected to grow at a CAGR of 7.9% during the forecast period of 2023-2031, driven by the growing awareness of rare diseases.

 

Atypical Teratoid Rhabdoid Treatment Market: Insights

Atypical Teratoid Rhabdoid (ATRT) is a primary tumour in the central nervous system (CNS). It begins in the brain or spinal cord. Primary CNS tumours are graded based on the location of the tumour, the type of tumour, the extent of tumour spread, genetic findings, the patient's age, and the amount of tumour that remains after surgery, if surgery is possible.

 

ATRTs are all considered Grade IV tumours. This indicates that they are malignant (cancerous) and rapidly growing. Cancer is a genetic disease, which means that it is caused by changes in genes that control how our cells function. In many types of cancer, genes can be mutated (changed), causing cancer cells to grow and spread. 

 

Majority of ATRTs are caused by mutations in the SMARCB1 gene (also called INI1). This gene normally sends signals to proteins that inhibit tumour growth. SMARCB1 does not function properly in ATRTs, and tumour growth is uncontrolled. SM ARCB1 is sometimes found in a person's DNA, indicating that they are born with it. ATRTs can grow very quickly. They frequently spread to other areas of the CNS via cerebrospinal fluid (CSF).

 

The symptoms of an ATRT vary, depending on the location of the tumour and the age of the person. Some of the most common symptoms are as follows:

 

  • Headaches
  • Vomiting
  • Variations in Activity Levels
  • Loss of Equilibrium
  • Increased Size of the Head

 

Symptoms usually worsen quickly as the ATRTs grow quickly.

 

According to the market research report, the atypical teratoid rhabdoid treatment market can be categorised into the following segments:

 

Market Breakup by Treatment Method

  • Surgery
  • Chemotherapy
  • Radiation
  • Targeted Immunotherapy

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Atypical Teratoid Rhabdoid Epidemiology

ATRTs can occur likewise in children and adults but they are extremely rare in both the age groups. This tumour affects an estimated 596 people in the United States. ATRTs are more prevalent in men than in women.

 

Global Atypical Teratoid Rhabdoid Therapeutic Landscape

The first line of treatment for an ATRT is surgery. The surgery aims at obtaining tissue to determine the tumour and its type and to remove the tumour to the largest extent without exacerbating the patient's symptoms.

 

Following surgery, people with ATRTs typically receive additional treatments, such as radiation, chemotherapy, or clinical trials. Clinical trials involving new chemotherapy, targeted therapy, or immunotherapy drugs may also be available as a treatment option. The patient's healthcare team decides on treatments based on the patient's age, remaining tumour after surgery, tumour type, and tumour location.

 

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers and Constraints

The population growing awareness of rare and genetic disorders is expected to drive the demand for the market. The number of leading pharmaceutical companies, with products in clinical trials for the treatment of atypical teratoid rhabdoid, will drive the market growth. 

 

The growth of the market can be hampered by the small patient population available for clinical trials.

 

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Competitive Landscape

The report gives an in-depth analysis of the key players involved in the Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

 

  • Takeda Pharmaceutical Company
  • Vyriad Inc
  • Novartis Oncology
  • Istari Oncology Inc.
  • Secura Bio, Inc.
  • Pfizer, Inc.
  • Ipsen Pharma
  • Exelixis, Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Method
  • Route of Administration
  • Treatment Channel
  • Region
Breakup by Treatment Method
  • Surgery
  • Chemotherapy
  • Radiation
  • Targeted Immunotherapy
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Takeda Pharmaceutical Company
  • Vyriad Inc.
  • Novartis Oncology
  • Istari Oncology Inc.
  • Secura Bio, Inc.
  • Pfizer, Inc.
  • Ipsen Pharma
  • Exelixis, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 5
5    Patient Profile
    5.1    Patient Profile Model 
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    6.1    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Overview
    6.2    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Analysis 
        6.2.1    Market Overview
            6.2.1.1    Global Historical Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Value (2016-2022) 
            6.2.1.2    Global Forecast Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Value (2023-2031)
    6.3    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market by Treatment Method 
        6.3.1    Surgery
        6.3.2    Chemotherapy
        6.3.3    Radiation
        6.3.4    Targeted Immunotherapy
    6.4    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market by Route of Administration
        6.4.1    Oral
        6.4.2    Parenteral
        6.4.3    Intravitreal
        6.4.4    Subretinal
        6.4.5    Topical
        6.4.6    Molecule Type
    6.5    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market by Treatment Channel
        6.5.1    Public
        6.5.2    Private
    6.6    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market by Region
        6.6.1    Market Overview
            6.6.1.1    North America 
                6.6.1.1.1    Historical Trend (2016-2022)
                6.6.1.1.2    Forecast Trend (2023-2031)
            6.6.1.2    Europe
                6.6.1.2.1    Historical Trend (2016-2022)
                6.6.1.2.2    Forecast Trend (2023-2031)
            6.6.1.3    Asia Pacific
                6.6.1.3.1    Historical Trend (2016-2022)
                6.6.1.3.2    Forecast Trend (2023-2031)
            6.6.1.4    Latin America
                6.6.1.4.1    Historical Trend (2016-2022)
                6.6.1.4.2    Forecast Trend (2023-2031)
            6.6.1.5    Middle East and Africa
                6.6.1.5.1     Historical Trend (2016-2022)
                6.6.1.5.2    Forecast Trend (2023-2031)
7    North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    7.1    United States of America
        7.1.1    Historical Trend (2016-2022)
        7.1.2    Forecast Trend (2023-2031)
    7.2    Canada 
        7.2.1    Historical Trend (2016-2022)
        7.2.2    Forecast Trend (2023-2031)
8    Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    8.1    United Kingdom
        8.1.1    Historical Trend (2016-2022)
        8.1.2    Forecast Trend (2023-2031)
    8.2    Germany
        8.2.1    Historical Trend (2016-2022)
        8.2.2    Forecast Trend (2023-2031)
    8.3    France
        8.3.1    Historical Trend (2016-2022)
        8.3.2    Forecast Trend (2023-2031)
    8.4    Italy
        8.4.1    Historical Trend (2016-2022)
        8.4.2    Forecast Trend (2023-2031)
9    Asia Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    9.1    China
        9.1.1    Historical Trend (2016-2022)
        9.1.2    Forecast Trend (2023-2031)
    9.2    Japan
        9.2.1    Historical Trend (2016-2022)
        9.2.2    Forecast Trend (2023-2031)
    9.3    India
        9.3.1    Historical Trend (2016-2022)
        9.3.2    Forecast Trend (2023-2031)
    9.4    ASEAN
        9.4.1    Historical Trend (2016-2022)
        9.4.2    Forecast Trend (2023-2031)
    9.5    Australia
        9.5.1    Historical Trend (2016-2022)
        9.5.2    Forecast Trend (2023-2031)
10    Latin America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    10.1    Brazil
        10.1.1    Historical Trend (2016-2022)
        10.1.2    Forecast Trend (2023-2031)
    10.2    Argentina
        10.2.1    Historical Trend (2016-2022)
        10.2.2    Forecast Trend (2023-2031)
    10.3    Mexico
        10.3.1    Historical Trend (2016-2022)
        10.3.2    Forecast Trend (2023-2031)
11    Middle East and Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market
    11.1    Saudi Arabia
        11.1.1    Historical Trend (2016-2022)
        11.1.2    Forecast Trend (2023-2031)
    11.2    United Arab Emirates
        11.2.1    Historical Trend (2016-2022)
        11.2.2    Forecast Trend (2023-2031)
    11.3    Nigeria
        11.3.1    Historical Trend (2016-2022)
        11.3.2    Forecast Trend (2023-2031)
    11.4    South Africa
        11.4.1    Historical Trend (2016-2022)
        11.4.2    Forecast Trend (2023-2031)
12    Current Scenario Evaluation and Regulatory Framework
    12.1    Emerging Therapies and Clinical Trials 
    12.2    Patent Landscape  
        12.2.1    Patent Overview 
            12.2.1.1    Patent Status and Expiry 
            12.2.1.2    Timelines from Drug Development to Commercial Launch 
            12.2.1.3    New Drug Application 
                12.2.1.3.1    Documentation and Approval Process 
        12.2.2    Cost of Treatment 
        12.2.3    Regulatory Framework 
            12.2.3.1    Regulatory Overview 
                12.2.3.1.1    US FDA 
                12.2.3.1.2    EU EMA 
                12.2.3.1.3    INDIA CDSCO 
                12.2.3.1.4    JAPAN PMDA 
                12.2.3.1.5    Others
13    Challenges & Unmet Needs
    13.1    Treatment Pathway Challenges
    13.2    Compliance and Drop- out Analysis
    13.3    Awareness and Prevention Gaps
14    Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces
    14.4    Key Demand Indicators
    14.5    Key Price Indicators
    14.6    Market Events, Initiatives & Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Takeda Pharmaceutical Company
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Vyriad Inc.
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3     Novartis Oncology
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4     Istari Oncology Inc.
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5      Secura Bio, Inc.
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6      Pfizer, Inc.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Ipsen Pharma
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Exelixis, Inc.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
16    Recommendations and Discussion
17    Atypical Teratoid Rhabdoid Tumours (ATRT) Drug Distribution Model (Additional Insight)

    17.1    Overview 
    17.2    Potential Distributors 
    17.3    Key Parameters for Distribution Partner Assessment 
18    Payment Methods (Additional Insight)
    18.1    Government Funded
    18.2    Private Insurance
    18.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market is likely to grow at a CAGR of 7.9% during the forecast period of 2023-2031.

The population growing awareness of rare and genetic disorders is expected to drive the demand for the treatment.

The treatment methods used in the market include surgery, chemotherapy, radiation, and targeted immunotherapy.

The different treatment methods include oral, parenteral, intravitreal, subretinal, topical, and molecule type.

The major regional markets include North America, Europe, Middle East and Africa, Asia Pacific, Latin America.

The treatment channels can be divided into public and private.

Small population available for the clinical trials will restrain the growth of the market.

ATRTs can occur in children and adults but they are extremely rare in both age groups. There have only been 50 adult cases reported. This tumour affects an estimated 596 people in the United States.

Atypical teratoid rhabdoid tumours (ATRTs) are the most common type of malignant brain tumour in children under the age of one year. They are most diagnosed in infants and toddlers as young as 1 or 2 years old. They account for about 1-2% of all paediatric brain tumours in children under the age of 16.

Takeda Pharmaceutical Company, Vyriad Inc, Novartis Oncology, Istari Oncology Inc., Secura Bio, Inc., Pfizer, Inc., Ipsen Pharma, and Exelixis, Inc., among others are the key players in the market.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER